1. Home
  2. AKBA vs DSP Comparison

AKBA vs DSP Comparison

Compare AKBA & DSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$0.57

Market Cap

248.3M

Sector

Health Care

ML Signal

N/A

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

N/A

Current Price

$12.05

Market Cap

272.1M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
AKBA
DSP
Founded
2007
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
248.3M
272.1M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
AKBA
DSP
Price
$0.57
$12.05
Analyst Decision
Buy
Strong Buy
Analyst Count
6
11
Target Price
$3.25
★ $19.32
AVG Volume (30 Days)
★ 9.5M
376.6K
Earning Date
11-05-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
93.94
★ 157.14
EPS
N/A
★ N/A
Revenue
N/A
★ $344,201,000.00
Revenue This Year
N/A
$26.65
Revenue Next Year
N/A
$21.65
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 19.00
52 Week Low
$0.36
$8.72
52 Week High
$1.84
$14.80

Technical Indicators

Market Signals
Indicator
AKBA
DSP
Relative Strength Index (RSI) 41.52 42.67
Support Level $0.54 $12.11
Resistance Level $1.00 $12.45
Average True Range (ATR) 0.07 0.81
MACD -0.01 -0.14
Stochastic Oscillator 45.81 35.52

Price Performance

Historical Comparison
AKBA
DSP

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising technology company engaged in providing a cloud-based demand-side platform (DSP) for programmatic advertising. The company enables marketers and advertising agencies to plan, buy, and measure digital advertising campaigns across multiple channels, including connected TV, streaming audio, mobile, desktop, and digital out-of-home. Its platform leverages data integrations and proprietary identity solutions to deliver targeted advertising, audience insights, and performance measurement.

Share on Social Networks: